Insulin resistance as a cause of hepatic fibrogenesis and carcinogenesis


private documents

About the project

Contractor: The Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI)

Program: IDEI

Domain: Health

Coordinator: UMF “Carol Davila” Bucharest

Project director: Prof. Dr. Vlad Ratziu

Project ID: PN-II-ID-PCE-2011-3-0917/Contract no. 297/05.10.2011

Duration: 2011 - 2014

State budget: 1.500.000 RON

Co-financing budget: 0


About the project

The SteatoComp project's objective is to evaluate the relationship between obesity, diabetes and liver damage. The project targets three aspects: 1) the current epidemiological situation and characteristics of HCC occurred in patients with non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH); 2) the impact characteristics of metabolic syndrome and NAFLD / NASH histologically diagnosed on clinical progression of chronic hepatitis B and C; 3) Optimization and validation of non-invasive diagnostic algorithms of non-alcoholic severe statohepatitis in patients at risk for NAFLD.

Scientific Methods

The clinical research will be conducted prospectively in a single academic center, respectively Clinic of Internal Medicine and Nephrology Fundeni, University of Medicine and Pharmacy "Carol Davila" Bucharest. The first and third objective results will be compared with those collected in the European register of hepatocellular carcinoma occurred in patients with NASH and those of multinational prospective cohort of patients with steatosis, metabolic risk factors and NAFLD histologically documented. These cohorts are currently being developed within the European Consortium funded by the FP7 program called FLIP (inhibitor progression of fatty liver), coordinated by Prof. Dr. Vlad Ratziu.


News and events related to project implementation.

  • First stage will end on December 2012.
  • Future events: to be announced.